

An Enantiodivergent Synthesis of Fused Bicyclo[2.2.1]heptane Lactones *via* an Asymmetric Diels–Alder Reaction

Yoshitsugu Arai, Makoto Matsui, and Toru Koizumi*

Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Sugitani 2630, Toyama 930-01, Japan

An enantiodivergent synthesis of the bicyclo[2.2.1]heptane lactone (**2**) is described, by regioselective reduction of the Diels–Alder adducts (**3**) and (**4**) with di-isobutylaluminium hydride followed by reductive elimination of the chiral auxiliary, 10-mercaptoisoborneol (**9**) through reaction with samarium(II) iodide.

The synthesis of chiral 7-oxa- and bicyclo[2.2.1]heptane derivatives is attracting much attention because of their biological properties, *e.g.* inhibitory effects such as prostaglandin/thromboxane receptor antagonist properties.¹ For the preparation of chiral 7-oxabicyclo[2.2.1]heptane derivatives, the chiral lactone (**1**) has been widely employed as a useful intermediate for their syntheses because of its availability through chemical² or enzymatic^{3–5} resolution. In contrast, despite its promise as a building block for synthesis,⁶ there are few reports of the preparation of the chiral bicyclo[2.2.1]heptane lactone (**2**). The first successful route to the (+)-lactone (**2**) reported was by enzymatic oxidation of a racemic diol.⁷ Recently both enantiomers of (**2**) were synthesized starting with D-mannitol.⁸ Herein, we disclose a short, enantiodivergent route to the lactone (**2**), which makes use of the adducts (**3**) and (**4**) derived from cyclopentadiene and the sulphoxide (**5**)⁹ (see Scheme). We have also devised an efficient method for reductive elimination of the chiral auxiliary, 10-mercaptoisoborneol (**9**) by the use of samarium(II) iodide.


The adduct (**3**), m.p. 126–127 °C, $[\alpha]_D +36.8^\circ$, prepared by the previously described method [C_5H_6 , (**5**), $ZnCl_2$, $-40 \rightarrow -20$ °C, 3 h],⁹ was converted into the lactone (**6**),[†] m.p. 224–225 °C, $[\alpha]_D +44.2^\circ$, by regioselective reduction with di-isobutylaluminium hydride [DIBAL (4 equiv.), -78 °C \rightarrow room temp., 48 h] in 61% yield as the sole product.‡ Deoxygenation of the sulphanyl group in (**6**) using either

phosphorus tribromide or zinc–acetic acid proceeded smoothly, but was accompanied by concomitant skeletal rearrangement of the isobornyl residue. Fortunately samarium(II)-induced reduction¹⁰ of (**6**) [SmI_2 (5 equiv.), tetrahydrofuran, $HOBu^t$, room temp., 10 min] proceeded smoothly to give the (+)-lactone (**8**), m.p. 122–124 °C, $[\alpha]_D +143.9^\circ$ [lit.,⁷ m.p. 120–122 °C, $[\alpha]_D +143.2^\circ$ (*c* 5.2, $CHCl_3$)] in 98% yield. At this stage the chiral auxiliary, (–)-10-mercaptoisoborneol (**9**) was recovered in high yield.§ Hydrogenation of the (+)-lactone (**8**) (5% Pd–C, EtOH, room temp., 2 h) furnished the (+)-lactone (**2**), m.p. 146–147 °C, $[\alpha]_D +150.4^\circ$ [lit.,⁸ $[\alpha]_D^{25} +153.28^\circ$ (*c* 1.01, $CHCl_3$)] in quantitative yield. To our knowledge, no reports of a one-step procedure involving treatment with SmI_2 to

† All new compounds reported here gave satisfactory spectral and analytical data. Optical rotations were taken in $CHCl_3$ (*c* 1.0) at 25 °C unless otherwise indicated.

‡ In this reduction the amount of DIBAL used and the reaction temperature was critical. Under the different conditions [DIBAL (2.2–4 equiv.), -78 °C, 3–22 h], the alcohol (**7**) was produced, along with variable amounts of (**6**).

§ The disulphide (**10**) was also recovered [ratio (**9**):(**10**) ~4:1]. The reaction was carried out with Bu^tOH as a proton source. However, when SmI_2 was allowed to react in the absence of Bu^tOH , only traces of (**9**) were isolated: under these conditions (**10**) was produced exclusively.



Scheme. Reagents: i, ZnCl₂, CH₂Cl₂ then C₅H₆; ii, Bu¹₂AlH, toluene; iii, SmI₂, tetrahydrofuran, HOBu¹; iv, H₂, 5% Pd-C, HOEt; v, C₅H₆, CH₂Cl₂.

eliminate the sulphonyl group attached to the quaternary carbon atom have appeared.*

Alternatively, the reaction of (5) with cyclopentadiene (30 equiv., CH₂Cl₂, room temp., 19 h) without Lewis acid gave the adduct (4), m.p. 124–125 °C, [α]_D +106.2°, in 68% yield, accompanied by small amounts of minor diastereoisomers (3) and (11) [19%, ratio (3):(11) 1:1.2]. The diastereoisomeric excess of the *exo* sulphonydes (4) and (3) was 84%. Reduction of

(4) with DIBAL produced the lactone (12), m.p. 179–180 °C, [α]_D -47.6°, in 88% yield. Treatment of the sulphoxide (12) with samarium(II) iodide (tetrahydrofuran, HOBu¹, room temp., 10 min) gave the (-)-lactone (8), m.p. 121–123 °C, [α]_D -135.9°, in quantitative yield. Hydrogenation of (-)-(8) yielded the (-)-lactone (2), m.p. 149–150 °C, [α]_D -151.0° (c 0.95) {lit.,⁸ [α]_D²⁶ -156.21° (c 0.81, CHCl₃)}.

Thus, an enantiodivergent synthesis of the useful chiral lactones (2) and (8) has been achieved starting from the sulphoxide (5) in a few steps. The method using samarium(II) iodide allows a great versatility in the elimination of a sulphonyl group attached to the α-carbonyl quaternary carbon atom. In addition, the reduction has the advantage that the chiral thiol can be recovered. Further transformation of (2) and (8) into biologically active compounds is in progress.

Experimental

(+)-(2S,3R)-cis-endo-3-(Hydroxymethyl)bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Lactone (8).—SmI₂ in tetrahydrofuran (0.08M; 18 ml) was added to compound (6) (100 mg) and Bu¹OH (0.11 ml) at room temperature under argon. After 10 min cold 1M hydrochloric acid (30 ml) was added to the mixture. The aqueous layer was extracted with chloroform (3 × 20 ml). The organic phase was washed with brine, dried, and evaporated under reduced pressure to leave a white solid, which was purified by column chromatography on silica gel (8 g). The fraction eluted with 25% AcOEt in hexane (v/v) afforded compounds (9) and (10) [50 mg; ratio (9):(10) 81:19] and (+)-(8) (42 mg, 98%) as a white powder (hexane–AcOEt), m.p. 122–124 °C.

Acknowledgements

We thank the Ministry of Education, Science and Culture (to T. K.) and the Research Foundation for Pharmaceutical Sciences (to Y. A.) for financial support.

References

- For a review, see: A. M. Lefer, *Drugs Today*, 1985, **21**, 283.
- J. Das, M. F. Haslanger, J. Z. Gougoutas, and M. F. Malley, *Synthesis*, 1987, 1100.
- J. B. Jones and C. J. Francis, *Can. J. Chem.*, 1984, **62**, 2578.
- R. Bloch, E. Guibe-Jampel, and C. Girard, *Tetrahedron Lett.*, 1985, **26**, 4087.
- S. Hagishita and K. Seno, *Chem. Pharm. Bull.*, 1989, **37**, 327.
- M. Narisada, M. Ohtani, F. Watanabe, K. Uchida, H. Arita, M. Doteuchi, K. Hanasaki, H. Kakushi, K. Otani, and S. Hara, *J. Med. Chem.*, 1988, **31**, 1847; K. Furuta, S. Hayashi, Y. Miwa, and H. Yamamoto, *Tetrahedron Lett.*, 1987, **28**, 5841; N. Hamanaka, T. Seko, T. Miyazaki, M. Naka, K. Furuta, and H. Yamamoto, *ibid.*, 1989, **30**, 2399.
- K. P. Lok, I. J. Jakovac, and J. B. Jones, *J. Am. Chem. Soc.*, 1985, **107**, 2521.
- S. Takano, K. Inomata, A. Kurotaki, T. Ohkawa, and K. Ogasawara, *J. Chem. Soc., Chem. Commun.*, 1987, 1720.
- Y. Arai, K. Hayashi, T. Koizumi, M. Shiro, and K. Kuriyama, *Tetrahedron Lett.*, 1988, **29**, 6143.
- P. Girard, J. L. Namy, and H. B. Kagan, *J. Am. Chem. Soc.*, 1980, **102**, 2693; G. A. Molander and G. Hahn, *J. Org. Chem.*, 1986, **51**, 1135; J. Inanaga, *Yuki Gosei Kagaku Kyokai Shi*, 1989, **47**, 200.

* Molander reported that 2-methyl-2-phenylsulphonylcyclohexanone was unsuitable for reduction with SmI₂ and gave a complex product mixture: see ref. 10.